Canadian firm Tilray (NASDAQ:TLRY) has obtained the support of global leading brewer Anheuser-Busch InBev SA/NV (NYSE:BUD) to develop cannabis-infused beverages.

On Wednesday (December 19), the cannabis licensed producer (LP) confirmed a research partnership to create tetrahydrocannabinol (THC) and cannabidiol (CBD) infused non-alcoholic drinks for the Canadian adult-use market.


This new deal cements the added interest from the beverage and other established industries into the cannabis space.

Tilray and AB InBev will invest up to US$50 million in the new venture. The collaboration will be overseen by Tilray’s recreational subsidiary High Park and AB InBev’s subsidiary Labatt Breweries of Canada.

Kyle Norrington, president of Labatt Breweries of Canada, said in a statement the company wants to stand by “the highest standards of product quality and responsible marketing” as Canadians begin consuming these beverages.

Edibles and infused products are scheduled to become legal in Canada at some point in 2019.

Brendan Kennedy, CEO of Tilray, said he was delighted for this partnership and will strive for a responsible approach to the creation and promotion of these drinks.

Shares of Tilray dropped during Wednesday’s trading session by 7.19 percent to a closing price of US$71 per share.

However, during after hours trading, the stock jumped up 10.49 percent for a price of US$78.45.

Meanwhile, shares of the parent company for AB InBev in New York rose a marginal 0.29 percent on after hours trading. Over a year-to-date period, stock of the beverage company has dropped nearly 40 percent.

The pursuit of the cannabis-infused beverage market is a crowded one with several leading LPs aspiring to serve this market, while a plenitude of smaller companies have also shares intentions to offer beverages.

Most notably, Canopy Growth (NYSE:CGC,TSX:WEED) and Hexo (TSX:HEXO) previously obtained partnerships with large beverage companies Constellation Brands (NYSE:STZ) and Molson Coors Brewing (NYSE:TAP,TSX:TAP).

Kris Dahl, VP of corporate development with Sproutly Canada (CSE:SPR), a company entirely focused on technologies for cannabis beverages, previously told the Investing News Network (INN) the problem with current cannabis beverages is it can take up to 30 or 45 minutes for the effects to kick in.

“Some people are impatient looking for that effect so they drink too much and when it finally hits, they are out of it for a long, long time,” Dahl said.

Similar to Hexo’s deal with Molson, Tilray’s joint venture will be managed by both the cannabis and beverage firms.

Unlike Constellation’s C$5 billion investment into Canopy, no shares or stake in the cannabis company are being exchanged in Tilray’s arrangement with its beverage partner.

Kennedy told the the Globe and Mail Tilray’s is not looking to be acquired at the moment and prefers the research deal in place.

This new deal comes on the heels of a new collaboration agreement between Tilray and generic pharmaceutical company Sandoz AG, a member of the Novartis (NYSE:NVS) group.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less

The following issues have been halted by IIROC:

Company: Revive Therapeutics Ltd.

Keep reading... Show less